The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
ATKINSON, ROBERT S.;TUGHAN, GARY, J. CHEM. SOC. PERKIN TRANS.,(1987) N 12, 2787-2796
作者:ATKINSON, ROBERT S.、TUGHAN, GARY
DOI:——
日期:——
US7750151B2
申请人:——
公开号:US7750151B2
公开(公告)日:2010-07-06
Asymmetric induction in addition of N-nitrenes to alkenes: 2-(chiral)substituted benzimidazole-derived N-nitrene additions to alkenes
作者:Robert S. Atkinson、Gary Tughan
DOI:10.1039/p19870002787
日期:——
Oxidation of the optically active 1-aminobenzimidazoles (5)–(7) with lead tetra-acetate in the presence of various prochiral alkenes yields mixtures of the diastereoisomeric aziridines with little asymmetricinduction (Table). Oxidation of theracemic 1-amino-2-(1,2,2-trimethylpropyl)-1H-benzimidazole (12) in the presence of α-methylene-γ-butyrolactone (1) yields the stereoisomeric azirid (16) in a
作者:Robert S. Atkinson、John Fawcett、David R. Russell、Gary Tughan
DOI:10.1039/c39860000832
日期:——
Oxidation of the 2-substituted N-amainobenzimidazole (5) in the presence of prochiral alkenes gives aziridines stereoselectively: addition, to γ,γ-dimethyl-α-methylenebutyrolactone is stereospecific and the relative configuration of the two chiral centres in the product has been confirmed by a single crystal X-ray diffraction study and is in agreement with a transition state geometry resembling (11)